Considerations and challenges in defining optimal iron utilization in hemodialysis

Dialysis Advisory Group

Research output: Contribution to journalReview article

48 Citations (Scopus)

Abstract

Trials raising concerns about erythropoiesis-stimulating agents, revisions to their labeling, and changes to practice guidelines and dialysis payment systems have provided strong stimuli to decrease erythropoiesis-stimulating agent use and increase intravenous iron administration in recent years. These factors have been associated with a rise in iron utilization, particularly among hemodialysis patients, and an unprecedented increase in serum ferritin concentrations. The mean serum ferritin concentration among United States dialysis patients in 2013 exceeded 800 ng/ml, with 18% of patients exceeding 1200 ng/ml. Although these changes are broad based, the wisdom of these practices is uncertain. Herein, we examine influences on and trends in intravenous iron utilization and assess the clinical trial, epidemiologic, and experimental evidence relevant to its safety and efficacy in the setting of maintenance dialysis. These data suggest a potential for harm from increasing use of parenteral iron in dialysis-dependent patients. In the absence of well powered, randomized clinical trials, available evidence will remain inadequate for making reliable conclusions about the effect of a ubiquitous therapy on mortality or other outcomes of importance to dialysis patients. Nephrology stakeholders have an urgent obligation to initiate well designed investigations of intravenous iron in order to ensure the safety of the dialysis population.

Original languageEnglish (US)
Pages (from-to)1238-1247
Number of pages10
JournalJournal of the American Society of Nephrology
Volume26
Issue number6
DOIs
StatePublished - Jun 1 2015

Fingerprint

Renal Dialysis
Dialysis
Iron
Hematinics
Ferritins
Safety
Nephrology
Serum
Practice Guidelines
Intravenous Administration
Randomized Controlled Trials
Maintenance
Clinical Trials
Mortality
Population

All Science Journal Classification (ASJC) codes

  • Nephrology

Cite this

Considerations and challenges in defining optimal iron utilization in hemodialysis. / Dialysis Advisory Group.

In: Journal of the American Society of Nephrology, Vol. 26, No. 6, 01.06.2015, p. 1238-1247.

Research output: Contribution to journalReview article

@article{7ce939ccb1dd43a4b57471b5213f9daf,
title = "Considerations and challenges in defining optimal iron utilization in hemodialysis",
abstract = "Trials raising concerns about erythropoiesis-stimulating agents, revisions to their labeling, and changes to practice guidelines and dialysis payment systems have provided strong stimuli to decrease erythropoiesis-stimulating agent use and increase intravenous iron administration in recent years. These factors have been associated with a rise in iron utilization, particularly among hemodialysis patients, and an unprecedented increase in serum ferritin concentrations. The mean serum ferritin concentration among United States dialysis patients in 2013 exceeded 800 ng/ml, with 18{\%} of patients exceeding 1200 ng/ml. Although these changes are broad based, the wisdom of these practices is uncertain. Herein, we examine influences on and trends in intravenous iron utilization and assess the clinical trial, epidemiologic, and experimental evidence relevant to its safety and efficacy in the setting of maintenance dialysis. These data suggest a potential for harm from increasing use of parenteral iron in dialysis-dependent patients. In the absence of well powered, randomized clinical trials, available evidence will remain inadequate for making reliable conclusions about the effect of a ubiquitous therapy on mortality or other outcomes of importance to dialysis patients. Nephrology stakeholders have an urgent obligation to initiate well designed investigations of intravenous iron in order to ensure the safety of the dialysis population.",
author = "{Dialysis Advisory Group} and Charytan, {David M.} and Pai, {Amy Barton} and Chan, {Christopher T.} and Coyne, {Daniel W.} and Hung, {Adriana M.} and Csaba Kovesdy and Steven Fishbane and {American Society of Nephrology}, {Society of Nephrology}",
year = "2015",
month = "6",
day = "1",
doi = "10.1681/ASN.2014090922",
language = "English (US)",
volume = "26",
pages = "1238--1247",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "6",

}

TY - JOUR

T1 - Considerations and challenges in defining optimal iron utilization in hemodialysis

AU - Dialysis Advisory Group

AU - Charytan, David M.

AU - Pai, Amy Barton

AU - Chan, Christopher T.

AU - Coyne, Daniel W.

AU - Hung, Adriana M.

AU - Kovesdy, Csaba

AU - Fishbane, Steven

AU - American Society of Nephrology, Society of Nephrology

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Trials raising concerns about erythropoiesis-stimulating agents, revisions to their labeling, and changes to practice guidelines and dialysis payment systems have provided strong stimuli to decrease erythropoiesis-stimulating agent use and increase intravenous iron administration in recent years. These factors have been associated with a rise in iron utilization, particularly among hemodialysis patients, and an unprecedented increase in serum ferritin concentrations. The mean serum ferritin concentration among United States dialysis patients in 2013 exceeded 800 ng/ml, with 18% of patients exceeding 1200 ng/ml. Although these changes are broad based, the wisdom of these practices is uncertain. Herein, we examine influences on and trends in intravenous iron utilization and assess the clinical trial, epidemiologic, and experimental evidence relevant to its safety and efficacy in the setting of maintenance dialysis. These data suggest a potential for harm from increasing use of parenteral iron in dialysis-dependent patients. In the absence of well powered, randomized clinical trials, available evidence will remain inadequate for making reliable conclusions about the effect of a ubiquitous therapy on mortality or other outcomes of importance to dialysis patients. Nephrology stakeholders have an urgent obligation to initiate well designed investigations of intravenous iron in order to ensure the safety of the dialysis population.

AB - Trials raising concerns about erythropoiesis-stimulating agents, revisions to their labeling, and changes to practice guidelines and dialysis payment systems have provided strong stimuli to decrease erythropoiesis-stimulating agent use and increase intravenous iron administration in recent years. These factors have been associated with a rise in iron utilization, particularly among hemodialysis patients, and an unprecedented increase in serum ferritin concentrations. The mean serum ferritin concentration among United States dialysis patients in 2013 exceeded 800 ng/ml, with 18% of patients exceeding 1200 ng/ml. Although these changes are broad based, the wisdom of these practices is uncertain. Herein, we examine influences on and trends in intravenous iron utilization and assess the clinical trial, epidemiologic, and experimental evidence relevant to its safety and efficacy in the setting of maintenance dialysis. These data suggest a potential for harm from increasing use of parenteral iron in dialysis-dependent patients. In the absence of well powered, randomized clinical trials, available evidence will remain inadequate for making reliable conclusions about the effect of a ubiquitous therapy on mortality or other outcomes of importance to dialysis patients. Nephrology stakeholders have an urgent obligation to initiate well designed investigations of intravenous iron in order to ensure the safety of the dialysis population.

UR - http://www.scopus.com/inward/record.url?scp=84930433794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930433794&partnerID=8YFLogxK

U2 - 10.1681/ASN.2014090922

DO - 10.1681/ASN.2014090922

M3 - Review article

VL - 26

SP - 1238

EP - 1247

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 6

ER -